Stockscreener 앱 받기
3.951
7.28%
0.271
전일 마감가:
$3.68
열려 있는:
$3.8
하루 거래량:
236.87K
Relative Volume:
0.43
시가총액:
$278.28M
수익:
$114.70K
순이익/손실:
$-12.82M
주가수익비율:
-1.4778
EPS:
-2.6735
순현금흐름:
$-45.71M
1주 성능:
+13.45%
1개월 성능:
+2.55%
6개월 성능:
+27.35%
1년 성능:
+136.41%
1일 변동 폭
$3.70
$3.98
1주일 범위
$3.45
$3.98
52주 변동 폭
$1.60
$6.60
Sab Biotherapeutics Inc Stock (SABS) Company Profile
명칭
Sab Biotherapeutics Inc
전화
305-845-2813
주소
777 W 41ST ST, MIAMI BEACH
Compare SABS vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SABS
Sab Biotherapeutics Inc
|
3.9599 | 258.61M | 114.70K | -12.82M | -45.71M | -2.6735 |
VRTX
Vertex Pharmaceuticals Inc
|
425.06 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.63 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
809.16 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
302.47 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.76 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-02 | 개시 | Rodman & Renshaw | Buy |
| 2025-12-19 | 개시 | Guggenheim | Buy |
| 2025-09-17 | 개시 | Leerink Partners | Outperform |
| 2025-05-14 | 재개 | H.C. Wainwright | Buy |
| 2024-10-09 | 개시 | Craig Hallum | Buy |
| 2024-08-28 | 개시 | Oppenheimer | Outperform |
| 2021-11-05 | 개시 | Chardan Capital Markets | Buy |
모두보기
Sab Biotherapeutics Inc 주식(SABS)의 최신 뉴스
SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET - Investing News Network
SAB Biotherapeutics Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
SAB BIO plans May 12 morning webcast on first-quarter results - Stock Titan
SAB Biotherapeutics and Emergent BioSolutions Sign Manufacturing and Supply Agreement for Drug Product Development - Minichart
SAB Biotherapeutics Signs Manufacturing Pact for SAB-142 - TipRanks
SAB Biotherapeutics (SABS) sets 5-year, $36M post-approval SAB-142 manufacturing pact - Stock Titan
Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142 - Bioscience Association Manitoba
Millennium entities disclose 3.43M shares in SAB Biotherapeutics (SABS) - Stock Titan
SAB Biotherapeutics (SABS) Expected to Announce Earnings on Friday - MarketBeat
SAB Biotherapeutics (NASDAQ: SABS) outlines 2026 virtual annual meeting and board elections - Stock Titan
Short Interest in SAB Biotherapeutics, Inc. (NASDAQ:SABS) Expands By 19.8% - MarketBeat
SAB Biotherapeutics (NASDAQ:SABS) Shares Down 1.4%Here's What Happened - MarketBeat
Emergent Inches Lower on New Deal with SAB - Baystreet.ca
Emergent BioSolutions (EBS) Secures $50M Agreement for SAB-142 D - GuruFocus
Emergent BioSolutions Wins $50 Million SAB Biotherapeutics Manufacturing Contract - citybiz
Type 1 diabetes candidate SAB-142 gets $50M manufacturing pact - Stock Titan
Guggenheim Maintains SAB Biotherapeutics(SABS.US) With Buy Rating, Maintains Target Price $15 - Moomoo
SABS Price Today: SAB Biotherapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Craig-Hallum Maintains SAB Biotherapeutics(SABS.US) With Buy Rating - Moomoo
H.C. Wainwright Maintains SAB Biotherapeutics(SABS.US) With Buy Rating, Maintains Target Price $7 - Moomoo
SAB Biotherapeutics Highlights Positive Phase 1 SAB-142 Results - TipRanks
SAB Biotherapeutics presents Phase 1 SAB-142 data showing C-peptide preservation, improved TIR - TradingView
[8-K] SAB Biotherapeutics, Inc. Reports Material Event - Stock Titan
In 4 adults with type 1 diabetes, SAB-142 lifted time in range to 85% - Stock Titan
SAB Biotherapeutics (SABS) Stock: Why Competitive Advantage (Trend Strengthens) 2026-04-20Diversification - Xã Vĩnh Công
SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress - Sahm
SAB Biotherapeutics Looks Undervalued If SAB-142 Delivers In Type 1 Diabetes - National Today
New type 1 diabetes data from SAB-142 heads to Brisbane meeting - Stock Titan
SAB BIO to Present Additional Data Supporting the Unique - GlobeNewswire
Breakouts Watch: Whats the profit margin of SAB Biotherapeutics Inc Equity WarrantWatch List & AI Powered Trade Plan Recommendations - baoquankhu1.vn
SABS Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Published on: 2026-04-12 12:29:27 - baoquankhu1.vn
Investment Report: Will SAB Biotherapeutics Inc outperform during market rallies2026 PostEarnings & High Win Rate Trade Tips - baoquankhu1.vn
SABS Options Volatility — NASDAQ:SABS - TradingView
Aug Chart Watch: Will SAB Biotherapeutics Inc stock recover after earnings2026 Sector Review & Real-Time Volume Triggers - baoquankhu1.vn
How does SAB Biotherapeutics (SABS) Stock react to Fed policy | Price at $3.75, Down 2.09%Social Momentum Signals - Newser
EV Market: Will SAB Biotherapeutics Inc outperform during market ralliesWeekly Risk Report & Precise Trade Entry Recommendations - baoquankhu1.vn
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Trading Action: Is Sinclair Incs growth already priced inQuarterly Growth Report & Weekly Hot Stock Watchlists - baoquankhu1.vn
Insider Trends: Is SAB Biotherapeutics Inc being accumulated by smart moneyMarket Risk Report & Stock Portfolio Risk Management - baoquankhu1.vn
Trading Recap: Is HADPP showing insider buyingQuarterly Market Summary & Growth Focused Entry Point Reports - baoquankhu1.vn
Is SAB Biotherapeutics (SABS) Stock Testing Support | Price at $3.89, Up 0.26%Trend Signals - Newser
SAB Biotherapeutics (NASDAQ:SABS) Coverage Initiated at Rodman & Renshaw - MarketBeat
Rodman & Renshaw initiates SAB Biotherapeutics stock with buy rating By Investing.com - Investing.com Canada
Rodman & Renshaw initiates SAB Biotherapeutics stock with buy rating - Investing.com
SABSW SEC FilingsSAB BIOTHERAPEUTICS INC 10-K, 10-Q, 8-K Forms - Stock Titan
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Short Interest Up 21.1% in March - MarketBeat
Published on: 2026-03-30 20:34:02 - baoquankhu1.vn
Published on: 2026-03-27 23:19:55 - baoquankhu1.vn
Institution Moves: Is SAB Biotherapeutics Inc stock a smart retirement pickIPO Watch & Pattern Based Trade Signal System - baoquankhu1.vn
SAB Biotherapeutics (SABS) CMO has common shares withheld for taxes - Stock Titan
Sab Biotherapeutics Inc (SABS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Sab Biotherapeutics Inc 주식 (SABS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Sessa Capital (Master), L.P. | Director |
Sep 29 '25 |
Option Exercise |
1.75 |
1,740,000 |
3,045,000 |
2,198,457 |
0.78%
3.01%
자본화:
|
볼륨(24시간):